• Login
    • Join
  • FOLLOW:
  • Subscribe Free
    • Magazine
    • eNewsletter
    Checkout
    • Magazine
    • News
    • Manufacturing
    • Packaging
    • Development
    • Compliance
    • Top 25
    • Directory
    • Microsites
    • Events
    • More
  • Magazine
  • News
  • Manufacturing
  • Packaging
  • Development
  • Compliance
  • Top 25
  • Directory
  • Microsites
  • Events
  • Current / Back Issue
    Features
    Editorial
    Columns
    Digital Edition
    eNewsletter Archive
    Our Team
    Editorial Guidelines
    Subscribe Now
    Advertise Now
    Top Features
    Bye-Bye China?

    Decentralized Trials Fuel AI Revolution in Clinical Research

    Self-Medication: Flexibility for Patients and Drug Manufacturers

    The Single-Use Mixing Landscape: Evaluating Your Options

    DCAT President Talks COVID-19, Drug Manufacturing and Innovation
    Breaking News
    Online Exclusives
    Industry News
    Collaborations & Alliances
    Promotions & Moves
    Trials & Filings
    Financial Reports
    Bio News & Views
    Custom Sourcing News
    Packaging & Tracking
    CRO News
    Live From Shows
    Top News
    Global Biosciences Co. Selects ValGenesis VLMS

    Eisai Appoints Chief Clinical Officer of Oncology Biz

    Nexelis Acquires GSK Vax Lab in Marburg

    Bone Therapeutics, Rigenerand Ink Cell Therapy Deal

    NovaQuest Private Equity Acquires CoreRx
    APIs
    Aseptic Processing
    Cleaning Validation
    Clinical Trial Materials
    Cytotoxics and High Potency Manufacturing
    Equipment
    Excipients
    Extractables and Leachables
    Facilities
    Fill/Finish
    Lyophilization
    Parenterals
    Process Development
    Process Validation
    Risk Management
    Scale-up/ Technology Transfer
    Solid Dosage/ Creams/ Ointments

    Lonza to Exit Pharma Softgels and Liquid-Filled Hard Capsules

    Cognate BioServices Announces Major Expansion

    Sanofi Unveils EUROAPI as Name of New European API Company

    Precision Medicine Group Acquires Project Farma

    Cytiva Delivers Modular Biologics Factory to Lonza
    Capsules
    Cold Chain Management
    Injectables
    Logistics
    Serialization
    Solid Dosage / Semi-solids
    Supply Chain
    Vials

    Catalent Acquires Acorda’s INBRIJA Manufacturing Operations

    Varcode, PL Developments Form Strategic ‘Smart Tag’ Pact

    COVID-19 Vaccine Distribution: The Air Cargo Industry’s Greatest Challenge

    Thermo Fisher Expands Clinical Supply Services in Europe

    Schreiner MediPharm Joins DoseID Consortium
    Analytical Services
    Bioanalytical Services
    Bioassay Developement
    Biologics, Proteins, Vaccines
    Biosimilars
    Chemistry
    Clinical Trials
    Drug Delivery
    Drug Development
    Drug Discovery
    Formulation Development
    Information Technology
    Laboratory Testing
    Methods Development
    Microbiology
    Preclinical Outsourcing
    R&D
    Toxicology

    Global Biosciences Co. Selects ValGenesis VLMS

    Nexelis Acquires GSK Vax Lab in Marburg

    The Future of Clinical Trials Series: Part I

    JS Bio and Etta Biotech Advancing Partnership

    Intravacc Completes Project for Provention Bio’s Vax Candidate
    Filtration & Purification
    GMPs/GCPs
    Inspections
    QA/QC
    Regulatory Affairs
    Validation

    Global Biosciences Co. Selects ValGenesis VLMS

    Gene Therapy Co. Selects ValGenesis' SaaS Platform

    The Year of COVID: How FDA Coped with a Worldwide Pandemic in 2020 and What to Expect in 2021

    Samsung Biologics Adopts Veeva Vault QMS to Unify Quality Management

    CDMO Cognate BioServices Teams Up with L7 Informatics
    Companies
    Categories
    Corporate Capabilities
    Add New Company
    Contract Service Directory Companies
    Alcami

    Syngene

    Flow Sciences

    Reed-Lane

    Adare Pharma Solutions
    Companies
    News Releases
    Posters
    Brochures
    Services
    Videos
    Case Study
    White Papers
    Jobs
    Contract Service Directory Companies
    Cytovance Biologics

    Reed-Lane

    Flow Sciences

    Adare Pharma Solutions

    Baxter BioPharma Solutions
    Webinars
    Live From Shows
    • Magazine
      • Current / Back Issue
      • Features
      • Editorial
      • Columns
      • Editorial Guidelines
      • Subscribe Now
      • Advertise Now
      • Enewsletter Archive
      • Digital Edition
    • Directory
      • Companies
      • Categories
      • Corporate Capabilities
      • Add Your Company
    • Manufacturing
      • APIs
      • Aseptic Processing
      • Cleaning Validation
      • Clinical Trial Materials
      • Cytotoxics and High Potency Manufacturing
      • Equipment
      • Excipients
      • Extractables and Leachables
      • Facilities
      • Fill/Finish
      • Lyophilization
      • Parenterals
      • Process Development
      • Process Validation
      • Risk Management
      • Scale-up/ Technology Transfer
      • Solid Dosage/ Creams/ Ointments
      • cGMP Manufacture
    • Packaging
      • Capsules
      • Cold Chain Management
      • Injectables
      • Logistics
      • Serialization
      • Solid Dosage / Semi-solids
      • Supply Chain
      • Vials
    • Development
      • Analytical Services
      • Bioanalytical Services
      • Bioassay Developement
      • Biologics, Proteins, Vaccines
      • Biosimilars
      • Chemistry
      • Clinical Trials
      • Drug Delivery
      • Drug Development
      • Drug Discovery
      • Formulation Development
      • Information Technology
      • Laboratory Testing
      • Methods Development
      • Microbiology
      • Preclinical Outsourcing
      • R&D
      • Toxicology
    • Compliance
      • Filtration & Purification
      • GMPs/GCPs
      • Inspections
      • QA/QC
      • Regulatory Affairs
      • Validation
    • Top 25 Pharma & BioPharma
    • Contract Pharma Direct
    • Breaking News
    • Online Exclusives
    • Slideshows
    • Experts Opinions
    • Surveys
      • Outsourcing Survey
      • Salary Survey
    • Glossary
    • Videos
    • Podcasts
    • White Papers
    • Infographics
    • Contract Pharma Conference
      • Contract Pharma Conference
      • Speakers
      • Exhibitors
      • Conference Sessions
    • Supplier Microsite
      • Companies
      • News Releases
      • Posters
      • Brochures
      • Services
      • Videos
      • Case Study
      • White Papers
    • eBook
    • Webinars
    • Events
      • Industry Events
      • Live from Show Events
      • Webinars
    • Classifieds / Job Bank
      • Classifieds
      • Job Bank
    • About Us
      • About Us
      • Contact Us
      • Advertise With Us
      • Privacy Policy
      • Terms of Use
    Features

    Single-use Technology Integral to Advancing Biomanufacturing

    Innovative process technologies are a necessity for today’s biopharmaceutical contract manufacturers

    Related CONTENT
    • Cytiva Delivers Modular Biologics Factory to Lonza
    • Catalent Acquires Acorda’s INBRIJA Manufacturing Operations
    • Catalent Divests Blow-Fill-Seal Sterile CDMO Business
    • The Year of COVID: How FDA Coped with a Worldwide Pandemic in 2020 and What to Expect in 2021
    • Impact of Decentralized Trials in Oncology Drug Development
    Nigel Walker, Thatu2019s Nice LLC / Nice Insight03.09.16
    Disposable bioprocessing equipment has been widely adopted in development and clinical manufacturing. Most biopharmaceutical companies have at least begun to explore its use for commercial manufacturing. The potential benefits are significant, particularly when it comes to small-volume manufacturing in modular facilities. Concerns about security of supply and standardization have yet to be addressed, however.

    New investments require new technologies
    Strong growth in the global biopharmaceutical market—from $162 billion in 2014 to $278 billion by 2020 at a compound annual growth rate (CAGR) of 9.4%—is driving investment in new facilities and expanded capacity/capabilities by both traditional biotechnology companies and conventional pharmaceutical manufacturers.1 Regeneron, Roche, Boehringer Ingelheim, Amgen, Eli Lilly, Bristol-Myers Squibb, Pfizer, Novartis and Genzyme have recently spent significant dollars on biomanufacturing capabilities.

    Contract manufacturers are, not surprisingly, following suit. The global biopharmaceutical contract manufacturing market is estimated to be growing at an overall, healthy, annualized rate of 8.3%2 with capacity for mammalian cell culture and microbial fermentation production expected to respectively increase by 14 and 16% by the end of 2016.3 Some of the contract development and manufacturing organizations (CDMOs) actively investing in biopharmaceutical production capabilities include, AbbVie, Catalent Pharma Solutions, Fujifilm Diosynth Biotechnologies, KBI Biopharma, and Patheon Biologics.

    Many of the new facilities being constructed today are quite different from those built during the early days of the biopharmaceutical industry. Advances in manufacturing technologies have led to as much as a 10-fold increase in productivity due to significantly higher titers. It is therefore now possible to produce in a 2000-L reactor what previously required a 20,000-L vessel, allowing for significant reduction in the scale for biopharmaceutical manufacturing facilities and associated capital expenditures.

    Meeting local demand
    A significant portion of the growth in demand for biologics is coming from emerging markets, and in many countries local manufacturing is required by the government. Technologies that can ensure consistent production in multiple locations are increasingly important. At the same time, demand for each individual biotherapeutic remains limited within a country, and thus technologies suitable for smaller production volumes are also needed.

    Highly efficient and cost-effective processes and facilities will be crucial for companies looking to be first to market with profitable new biosimilars. Due to the intense competition in this segment, each manufacturer is likely to end up with limited market share for each product, once again leading to the need for small-volume manufacturing capabilities.

    The most forward-thinking companies are also implementing continuous processing capabilities for both upstream and downstream operations in their new facilities. Continuous processes can help reduce overall manufacturing footprints and production times, provide more consistent product quality, and even result in lower overall costs.

    Many of these new facilities are also designed with multi-product manufacturing and/or fill finish capabilities. Technologies that enable the safe handling of many different products with different physical, chemical, and therapeutic properties without risk of cross contamination between batches are crucial in such production sites.

    Going beyond small-scale manufacturing
    Implementation of innovative process technologies is clearly a necessity for biopharmaceutical contract manufacturers. In particular, single-use technologies help to reduce the risk of contamination, reduce scheduling times, increase operational efficiencies, and reduce capital expenditures, including both fixed and consumables costs. Disposable systems come pre-sterilized, thus eliminating the need for cleaning and sterilization and significantly reducing setup and switchover times. As a result, they also provide flexibility and enable manufacturers to quickly change their portfolios in response to market needs. To put it in measurable terms, an example from 2015 showed that customers of Sartorius reported capital cost reductions of 40 to 50%, operating cost reductions of 20 to 30%, and acceleration of time-to-build by 30%, when compared with traditional stainless-steel technology, after employing single-use technologies for 10 years.4

    Disposable technologies are particularly ideal for scaling down biologic manufacturing processes, which as noted above is a key trend in the biopharmaceutical industry. Indeed, single-use technologies are well suited for use in modular facilities designed to enable high-quality production of biologic APIs and formulated products around the world, including in places where traditional facilities cannot be constructed.

    In fact, according to a 2015 report by BioPlan Associates, more than 90% of facilities use single-use/disposable technologies, and manufacturers and suppliers consider both disposable and stainless-steel options when planning their manufacturing strategies.5 In addition, more than two-thirds of biomanufacturers and suppliers (69%) reported improvements in biomanufacturing performance at their facilities in the previous 12 months due to the use of disposable devices.

    Of the announced plans for new and expanded biologics facilities listed above, the vast majority include the incorporation of some level of single-use technologies for one or more phases of production, from fed-batch and perfusion bioreactors for upstream API production to various separation, purification, and filtration devices for downstream processing to disposable fill/finish systems.

    Single-use technologies are seen as supporting flexible cGMP manufacturing and enabling efficient and rapid adjustment of production schedules and volumes and even system reconfigurations combined with ease of process replication and relocation to other global sites or transfer to contract manufacturers. These attributes also facilitate the implementation of key regulatory initiatives such as quality-by-design (QbD), the use of process analytical technology, and continuous processing. The ability to use a similar equipment configuration and the same materials for production equipment at the process development and commercial-scale manufacturing phases also simplifies process scale-up and can accelerate time to market.

    Interestingly, CMOs were more likely than branded drug manufacturers to adopt single-use technologies—86% vs. 66%, respectively. This phenomenon was attributed to the ease of use and the efficiency of these systems and devices when dealing with multiple products and bioprocesses that require fast turn-around times.5 Single-use systems provide CDMOs with more flexible production capacity in terms of rapid switching between product campaigns and the ability to manufacture over a wider range of production scales. Implementing single-use systems and integrating them into manufacturing operations is, in fact, the single most important biomanufacturing trend or operational area that the industry must focus on, according to CMO representatives surveyed by BioPlan Associates.6

    Hybrid approach and risk mitigation
    It is important to note, though, that there are limitations to single-use technology, and it is not always the most effective or economical solution. Many companies, in fact, take a hybrid approach, using a combination of disposable and reusable stainless steel/glass equipment. In general, in addition to economics, several factors are considered in determining whether single-use systems are appropriate for a given project; including whether existing equipment is available, the timing and budget for a project, the potential need for future replication of the process, and whether the process will be performed in a multiproduct facility.

    Technical Report Number 66—Application of Single Use Systems in Pharmaceutical Manufacturing—from the Parenteral Drug Association (PDA) describes a risk-based decision-making process for determining if implementation of single-use technologies is appropriate for a given process. It is based on QbD principles and involves a step-wise approach that considers factors such as the suitability and availability of particular single-use equipment systems/components, plus many different potential risks. If the answer to each question in the series is yes, then single-use technology is appropriate for the project and as a bonus the reasoning supporting implementation of disposable systems is well documented.

    Upstream vs. Downstream
    While single-use bioreactors are widely used in upstream cell-culture-based biopharmaceutical manufacturing processes, disposable technologies for microbial fermentation are less well developed. Fermentations are generally higher volume, which can be an issue for disposable bioreactors. Single-use solutions for common downstream operations are also more limited. For many downstream unit operations, large-scale single-use technologies that can handle the higher titers achieved upstream have not yet been introduced. Notably, disposable technology is also finding increasing use in final formulation and filling processes for both non-sterile products and those that require aseptic processing conditions.

    Suppliers of single-use technology systems are making rapid advances in developing effective downstream solutions. For example, various tangential flow filtration (TFF) devices are now commercially available that can be effectively combined with other downstream unit operations. Disposable, pre-packed chromatography columns have also been introduced to the market, and continuous chromatography systems (e.g. simulated moving bed (SMB), counter-current extraction) are being developed that have economics similar to single-use systems.

    Single-use equipment manufacturers are also focusing efforts on the development of bioreactors for adherent cell manufacturing for cell-based therapies, small-scale bioreactors for scale-down modeling in the laboratory, and a wider array of disposable sensors for real-time monitoring.

    Considering the risks
    While single-use technologies provide many benefits, they also carry risks that tend to be magnified on the commercial-scale and of greater importance when implemented at the final drug manufacturing stages. Of concern are leachables and extractables from the plastics used in disposable systems. Many issues with leachables and extractables have been addressed; however, as single-use technologies are increasingly employed at the commercial scale and in manufacturing processes close to the final drug product, the risks they present increase. Regulatory scrutiny is significantly heightened when using disposable technology for final formulation and filling processes compared to media preparation or cell culture, for example, and there is a need to demonstrate extractables/leachables performance.

    Change management is also an issue for single-use systems. Changes to reusable equipment are much easier to implement, largely because it can take much longer to assess extractables data and qualify modified disposable equipment. Both biopharmaceutical manufacturers and single-use suppliers must have rigorous change management procedures in place to ensure that disposable equipment consistently meets specifications for every application.

    At present there remains a lack of industry consensus on what data should be provided by suppliers, particularly given that needs can vary depending on whether the disposal systems are being used upstream, downstream, or for final filling operations. The regulatory requirements are also rather vague and tend to be considered on an individual basis. Discussions are underway to address such concerns (see more below).

    The risk of being committed to a single supplier of disposable equipment has also created concerns in the industry. In most cases, components from one supplier cannot be used with those of another. This lack of interoperability often forces drug manufacturers to use only one supplier or to purchase duplicate versions of the same components. In addition to increasing inventory management costs, this situation creates supply chain security concerns. In essence, suppliers of disposable equipment are as critical to ensuring that drug products reach patients as suppliers of key raw materials in terms of both reliable and on-time delivery and quality consistency.

    Many biopharmaceutical manufacturers that initially purchased single-use components from many different suppliers looking to maximize their options have come to realize the increased costs associated with maintaining such a large number of different part numbers. The trend today is consolidation and internal standardization on a set number of basic components that can be used to build the various configurations they require for different unit operations. In general, components/systems from suppliers that can guarantee dual sourcing through production at various sites are preferred.

    Tackling standardization issues
    Both interoperability and extractables/leachables are key topics under discussion by numerous industry groups and standards organizations seeking to find workable solutions for standardization. The Bioprocess Systems Alliance (BPSA), Biophorum Operations Group (BPOG), Parenteral Drug Association (PDA), US Pharmacopeial Convention (USP), International Organization for Standardization, ASTM International, and the American Society of Mechanical Engineers (with its Bioprocessing Equipment (BPE) group) are actively involved in developing workable standards related to the use of disposable technologies ranging from standardization of extractables and integrity testing, particulate control, change control/notification procedures, and product characteristics/specifications to increase interoperability.

    BPSA and BPOG, for instance, have joint User Requirement Specification and Change Notification Teams. The former is looking at quality requirements and product specifications, among other issues. A PDA team, meanwhile, has provided comments to ASTM as it works on its design verification standard. ASTM is also working on a standard for the determination and characterization of extractables from single-use materials with considerable input from BPOG and BPSA. ASME, ASTM and BPOG are looking at leachables, USP and ASTM are addressing sub-visible particles, and ASTM, ASME, and BPSA are working on system integrity testing issues.

    Many of these groups have published various technical documents and guidelines on these topics. For instance, BPSA developed a quality assurance template for establishing an agreement between a single-use supplier and biopharmaceutical manufacturer regarding quality consistency.  BPSA’s Quality Test Reference Matrices lists existing standards that are applicable to disposable technologies and should be referenced by suppliers in their quality procedures. BPSA also published the Guide to Gamma Irradiation and Sterilization of Single Use Systems and the Guide to the Observation, Measurement and Control of Particulates in Single Use

    Systems
    With respect to interoperability, there is discussion of developing standards that would enable a plug-and-play approach. Some suppliers are resistant to such standardization because they fear it will eliminate any opportunity to establish competitive advantage. Many, however, believe that such standardization would lead to greater efficiencies and lower costs, which in turn would encourage biologics manufacturers that have previously avoided disposable technology to adopt single-use systems and thus expand the market.

    Further growth expected
    According to the Nice Insight 2015 Pharmaceutical Equipment Study6, 76% of respondents (n=560) indicated that their companies spend over $50 million on equipment per year. A growing percentage of those dollars is being invested in single-use equipment. Indeed, respondents to a separate Nice Insight survey of biologics outsourcers indicated that they prefer single-use disposable reactors as often (67%) as they do stainless steel systems (68%)7 (see Figures 1, 2 and 3).

    If the various standards under development by industry groups representing both biopharmaceutical manufacturers and single-use suppliers evolve, growth of the disposable market may be quite significant. Technavio forecasts a high compound annual growth rate (CAGR) of 34.38% from 2014-2019 for the single-use bioprocessing system market.8 Transparency Market Research estimates that commercial cGMP manufacturing applications account for just 25% of the market.9 This segment is poised for significant growth, however, and will be a major driver of future market expansion. 

    References
    1. Persistence Market Research, “Global Biopharmaceuticals Market Will Reach US $278 Bn by 2020”, Press Release, July 27, 2015; http://www.persistencemarketresearch.com/mediarelease/biopharmaceutical-market.asp.
    2. Roots Analysis, “Biopharmaceutical Contract Manufacturing Market, 2015 – 2025”, Press Release, May 5, 2015; http://www.rootsanalysis.com/reports/view_document/biopharmaceutical-contract-manufacturing-market-2015-2025/92.html.
    3. Lupis JC and Langer ES. Critical Trends Driving BioManufacturing Production Strategies. Pharma Manufacturing. June 3, 2015. Accessed at: http://www.pharmamanufacturing. com/articles/2015/trends-driving-biomanufacturing-production-strategies/
    4. Hernandez R. Top Trends in Biopharmaceutical Manufacturing: 2015. Pharmaceutical Technology;39(6). June 2, 2015. Accessed at: http://www.pharmtech.com/top-trends-biopharmaceutical-manufacturing-2015
    5. Hammeke K. As Biologics Development Rise at Pharma Companies – What Does it Mean for Outsourcing? BioProcess Online. February 3, 2014. http://www.bioprocessonline.com/doc/as-biologics-development-rise-at-pharma-companies-what-does-it-mean-for-outsourcing-0001.
    6. Nice Insight 2015 Pharmaceutical Equipment Annual Study, April 2015.
    7. Ladage TJ. Bioreactor Preferences from an Outsourcing Perspective – Part I.  Pharma Manufacturing. February 5, 2015. Accessed at: http://www.pharmamanufacturing.com/articles/2015/bioreactor-outsourcing-perspective-part1/.
    8. Technavio. Global Single-use Bioprocessing System Market 2015-2019. Press Release, July 29, 2015.
    9. Transparency Market Research. Single-Use Bio-processing Systems Market – Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 – 2020. Press Release, October 21, 2015.

    Nigel Walker is managing director at That’s Nice LLC / Nice Insight. To learn more about Nice Insight contact Nigel at nigel@thatsnice.com or visit www.niceinsight.com.
    Related Searches
    • facility
    • Sterile
    • Pharma
    • equipment
    Suggested For You
    Cytiva Delivers Modular Biologics Factory to Lonza Cytiva Delivers Modular Biologics Factory to Lonza
    Catalent Acquires Acorda’s INBRIJA Manufacturing Operations Catalent Acquires Acorda’s INBRIJA Manufacturing Operations
    Catalent Divests Blow-Fill-Seal Sterile CDMO Business Catalent Divests Blow-Fill-Seal Sterile CDMO Business
    The Year of COVID: How FDA Coped with a Worldwide Pandemic in 2020 and What to Expect in 2021 The Year of COVID: How FDA Coped with a Worldwide Pandemic in 2020 and What to Expect in 2021
    Impact of Decentralized Trials in Oncology Drug Development Impact of Decentralized Trials in Oncology Drug Development
    Passage Bio Invests in Gene Therapy Manufacturing R&D Site Passage Bio Invests in Gene Therapy Manufacturing R&D Site
    Advancing Digital Endpoints in Clinical Trials Advancing Digital Endpoints in Clinical Trials
    Life Sciences Strive for Greater Agility Life Sciences Strive for Greater Agility
    Passage Bio, Catalent Begin cGMP Mfg. for Gene Therapies Passage Bio, Catalent Begin cGMP Mfg. for Gene Therapies
    Catalent Appoints Minakuchi Facility GM Catalent Appoints Minakuchi Facility GM
    Catalent Invests $10M in Isolator Capabilities to Expand Micronization Catalent Invests $10M in Isolator Capabilities to Expand Micronization
    Catalent Pharma Solutions Catalent Pharma Solutions
    Catalent, Blueprint Enter GAVRETO Commercial Supply Pact Catalent, Blueprint Enter GAVRETO Commercial Supply Pact
    Catalent Appoints Open Innovation, Biologics, Cell and Gene Therapy VP Catalent Appoints Open Innovation, Biologics, Cell and Gene Therapy VP
    Pii Appoints Business Development Director Pii Appoints Business Development Director

    Related Features

    • Biologics, Proteins, Vaccines | Biosimilars | Drug Development
      Biopharma Contract Manufacturing: Robust Growth Ahead

      Biopharma Contract Manufacturing: Robust Growth Ahead

      The biopharmaceutical contract manufacturing market is projected to reach $6.3 billion in 2020, and it will continue to grow over the next five years.
      William Downey, HighTech Business Decisions 11.17.20

    • Biosimilars
      Biosimilar Manufacturing Strategies

      Biosimilar Manufacturing Strategies

      Five steps to competing in a post-patent expiry era.
      George I’ons, Owen Mumford Pharmaceutical Services 09.09.20

    • Biosimilars
      The U.S. Biosimilars Market: Shaking the “Laggard” Label

      The U.S. Biosimilars Market: Shaking the “Laggard” Label

      Biosimilar uptake set to reshape the U.S. market
      Katya Svoboda and Bob Swann, ICON 05.05.20


    • Biologics, Proteins, Vaccines | Biosimilars
      Biopharma Over 20 Years

      Biopharma Over 20 Years

      A look at the key trends that have impacted the biopharma industry over the years.
      K. John Morrow, Jr. and Eric S. Langer, BioPlan Associates 11.20.19

    • Biologics, Proteins, Vaccines | Biosimilars
      Are Biotech Companies Strong Investments?

      Are Biotech Companies Strong Investments?

      Biotech capital raised via IPO has increased dramatically over the past couple of years.
      Jason Monteleone , CEO, Clinipace 05.07.19

    • Biosimilars
      Biosimilar  Market Trends

      Biosimilar Market Trends

      2017 was a record year for biosimilar approvals.
      Fiona Greer and Bruno Speder, SGS 09.11.18


    • Biologics, Proteins, Vaccines | Biosimilars | Drug Development
      Haste Makes Waste

      Haste Makes Waste

      When to sprint and when to breathe in the race from lab to clinic.
      Christian Cattaruzza, MilliporeSigma 09.11.18

    • Biologics, Proteins, Vaccines | Biosimilars
      Biopharma Manufacturing Markets

      Biopharma Manufacturing Markets

      Biomanufacturing contract services and supplies markets continue to expand
      Ronald A. Rader and Eric S. Langer, BioPlan Associates 05.08.18

    • Biologics, Proteins, Vaccines | Biosimilars
      Contract BioManufacturing in China: Creating a New Segment

      Contract BioManufacturing in China: Creating a New Segment

      An up-close look at China’s growing market for CMO services.
      Vicky Qing Xia and Leo Cai Yang, BioPlan Associates 04.10.18


    • Biologics, Proteins, Vaccines | Biosimilars | cGMP Manufacture
      Biopharmaceutical Contract Manufacturing Market

      Biopharmaceutical Contract Manufacturing Market

      The market continues to grow, projected to exceed $4 billion in 2017
      William Downey, President, HighTech Business Decisions 06.06.17

    • Aseptic Processing | Biosimilars | Drug Delivery | Logistics | Supply Chain
      Improving Packaging Processes to Meet Regulatory and Patient Needs

      Improving Packaging Processes to Meet Regulatory and Patient Needs

      The rise of advanced automation and packaging technologies
      06.02.16

    • Biosimilars | Drug Delivery | Injectables | Parenterals | Serialization | Supply Chain | Vials
      Contract Packaging Market Trends

      Contract Packaging Market Trends

      Contract packagers talk about hot growth areas and the looming 2017 DSCSA deadline
      Tim Wright, Editor 06.02.16


    • Biosimilars | Chemistry | Process Development | Supply Chain
      Biopharma CMO Market Trends

      Biopharma CMO Market Trends

      Continued strong growth in biopharma industry is being driven by biosimilars
      Tim Wright, Editor 06.02.16

    • Biosimilars | Clinical Trials | Formulation Development
      Critical Steps for Biosimilar Assessment

      Critical Steps for Biosimilar Assessment

      Establishing “finger-print like” biosimilarity prior to the clinic
      Fiona Greer, SGS 05.05.16

    • Biosimilars | Clinical Trials | Drug Development
      The Evolving Landscape of Drug Development in China

      The Evolving Landscape of Drug Development in China

      Innovation agenda includes expanded use of biosimulation
      Christine Yuying Gao and Ellen Leinfuss, Certara 05.05.16

    Trending
    • Lonza To Exit Pharma Softgels And Liquid-Filled Hard Capsules
    • The Future Of Clinical Trials Series: Part I
    • Grifols Begins COVID-19 Plasma Treatment Trial
    • Thermo Fisher Buys Novasep's Viral Vector Manufacturing Biz
    • NovaQuest Private Equity Acquires CoreRx
    Breaking News
    • Global Biosciences Co. Selects ValGenesis VLMS
    • Eisai Appoints Chief Clinical Officer of Oncology Biz
    • Nexelis Acquires GSK Vax Lab in Marburg
    • Bone Therapeutics, Rigenerand Ink Cell Therapy Deal
    • NovaQuest Private Equity Acquires CoreRx
    View Breaking News >
    CURRENT ISSUE

    November/December 2020

    • Modeling Process Safety Workflows in Pharmaceutical Manufacturing Scale-Up
    • Ensuring Quality During the Transfer and Scale Up of Rx Drugs
    • Inspecting the Unexpected
    • Cold Chain Trends
    • Catering for the Complex
    • Biopharma Contract Manufacturing: Robust Growth Ahead
    • DCAT President Talks COVID-19, Drug Manufacturing and Innovation
    • The Single-Use Mixing Landscape: Evaluating Your Options
    • Self-Medication: Flexibility for Patients and Drug Manufacturers
    • Decentralized Trials Fuel AI Revolution in Clinical Research
    • View More >

    Cookies help us to provide you with an excellent service. By using our website, you declare yourself in agreement with our use of cookies.
    You can obtain detailed information about the use of cookies on our website by clicking on "More information”.

    • About Us
    • Privacy Policy
    • Terms And Conditions
    • Contact Us

    follow us

    Subscribe
    Nutraceuticals World

    Latest Breaking News From Nutraceuticals World

    Ingredient Manufacturers Discuss the E-Sports Market
    Euromonitor Names Top Ten Trends for 2021
    Study Highlights Differences Between EPA's and DHA's Effect on Sleep
    Coatings World

    Latest Breaking News From Coatings World

    IGL Coatings Launches Graphene Reinforced Dual System Ceramic Coating
    Miller Paint Declares Simple Serenity its 2021 Color of the Year
    TAUBMANS Paint by PPG Releases ‘Chromatic Joy’ Palettes
    Medical Product Outsourcing

    Latest Breaking News From Medical Product Outsourcing

    Eitan Medical Receives FDA Clearance for Sapphire Infusion System
    Researchers Successfully ‘Fine Tune’ New Thermoplastic Biomaterial
    RSIP Vision Announces Versatile Medical Image Segmentation Tool
    Contract Pharma

    Latest Breaking News From Contract Pharma

    Global Biosciences Co. Selects ValGenesis VLMS
    Eisai Appoints Chief Clinical Officer of Oncology Biz
    Nexelis Acquires GSK Vax Lab in Marburg
    Beauty Packaging

    Latest Breaking News From Beauty Packaging

    Top Beauty Brands in the World—And Most Loved Fragrances
    P&G Reports Q2 Results
    A Lacquering Technique Makes Very Good Girl by Carolina Herrera Shine
    Happi

    Latest Breaking News From Happi

    Flow Launches Collagen Waters
    Associations Congratulate Biden & Harris
    David Stanko Joins JPMS
    Ink World

    Latest Breaking News From Ink World

    Morancé Soudure France Adds Comexi F2 MC 10-color Flexo Press
    THIMM Group Installs 1st Koenig & Bauer CorruFLEX
    Cowan Graphics Adds Fujifilm Inca OnsetX3 HS
    Label & Narrow Web

    Latest Breaking News From Label & Narrow Web

    Domino grows installation and service teams
    ABG keeps pace with demand with recruitment drive
    Acucote expands FSC-certified portfolio
    Nonwovens Industry

    Latest Breaking News From Nonwovens Industry

    First Quality Launches Incognito by Prevail
    Essity Launches Reusable Underwear Product
    Honeywell Delivered 225 Million Masks in December
    Orthopedic Design & Technology

    Latest Breaking News From Orthopedic Design & Technology

    DJO Acquires Trilliant Surgical
    FDA Breakthrough Device Designation Granted to Spiderwort's Spinal Cord Technology
    Bioventus Appoints SVP of Operations
    Printed Electronics Now

    Latest Breaking News From Printed Electronics Now

    UDC Subsidiary Adesis' Website Wins 2020 MarCom Platinum Award
    Roadsimple Modernizes Warehouse Ops with Zebra Technologies
    Graphene Flagship Launches Redesigned Website

    Copyright © 2021 Rodman Media. All rights reserved. Use of this constitutes acceptance of our privacy policy The material on this site may not be reproduced, distributed, transmitted, or otherwise used, except with the prior written permission of Rodman Media.

    AD BLOCKER DETECTED

    Our website is made possible by displaying online advertisements to our visitors.
    Please consider supporting us by disabling your ad blocker.


    FREE SUBSCRIPTION Already a subscriber? Login